Global Markets Direct’s, ‘Mitochondrial Diseases - Pipeline Review, H1 2014’, provides an overview of the Mitochondrial Diseases’s therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Mitochondrial Diseases, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Mitochondrial Diseases and special features on late-stage and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
- The report provides a snapshot of the global therapeutic landscape of Mitochondrial Diseases - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Mitochondrial Diseases and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Mitochondrial Diseases products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Mitochondrial Diseases pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products
Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Mitochondrial Diseases - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Mitochondrial Diseases pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table Of Contents
Mitochondrial Diseases - Pipeline Review, H1 2014 Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Mitochondrial Diseases Overview 6 Therapeutics Development 7 Pipeline Products for Mitochondrial Diseases - Overview 7 Pipeline Products for Mitochondrial Diseases - Comparative Analysis 8 Mitochondrial Diseases - Therapeutics under Development by Companies 9 Mitochondrial Diseases - Therapeutics under Investigation by Universities/Institutes 11 Mitochondrial Diseases - Pipeline Products Glance 12 Clinical Stage Products 12 Early Stage Products 13 Mitochondrial Diseases - Products under Development by Companies 14 Mitochondrial Diseases - Products under Investigation by Universities/Institutes 15 Mitochondrial Diseases - Companies Involved in Therapeutics Development 16 NeuroVive Pharmaceutical AB 16 Edison Pharmaceuticals, Inc. 17 ElexoPharm GmbH 18 Mitochondrial Diseases - Therapeutics Assessment 19 Assessment by Monotherapy Products 19 Assessment by Target 20 Assessment by Mechanism of Action 22 Assessment by Route of Administration 24 Assessment by Molecule Type 26 Drug Profiles 28 vatiquinone - Drug Profile 28 Product Description 28 Mechanism of Action 28 RandD Progress 28 OT-15 - Drug Profile 30 Product Description 30 Mechanism of Action 30 RandD Progress 30 MTP-131 - Drug Profile 31 Product Description 31 Mechanism of Action 31 RandD Progress 31 NVP-015 - Drug Profile 33 Product Description 33 Mechanism of Action 33 RandD Progress 33 Alkylaminoquinone Based Multifunctional Radical Quenchers - Drug Profile 34 Product Description 34 Mechanism of Action 34 RandD Progress 34 Eurostars Program - Drug Profile 35 Product Description 35 Mechanism of Action 35 RandD Progress 35 Drug for Mitochondrial Diseases - Drug Profile 36 Product Description 36 Mechanism of Action 36 RandD Progress 36 Drugs Targeting Cellular Energy Metabolism - Drug Profile 37 Product Description 37 Mechanism of Action 37 RandD Progress 37 Small Molecules for Mitochondrial Diseases - Drug Profile 38 Product Description 38 Mechanism of Action 38 RandD Progress 38 Mitochondrial Diseases - Recent Pipeline Updates 39 Mitochondrial Diseases - Dormant Projects 46 Mitochondrial Diseases - Discontinued Products 47 Mitochondrial Diseases - Product Development Milestones 48 Featured News and Press Releases 48 Mar 18, 2013: St George's University Of London Receives Â£3.3m MRC Grant For Developing New Treatment For Rare Metabolic Disorder 48 Appendix 49 Methodology 49 Coverage 49 Secondary Research 49 Primary Research 49 Expert Panel Validation 49 Contact Us 50 Disclaimer 50
List of Tables
Number of Products under Development for Mitochondrial Diseases, H1 2014 7 Number of Products under Development for Mitochondrial Diseases - Comparative Analysis, H1 2014 8 Number of Products under Development by Companies, H1 2014 10 Number of Products under Investigation by Universities/Institutes, H1 2014 11 Comparative Analysis by Clinical Stage Development, H1 2014 12 Comparative Analysis by Early Stage Development, H1 2014 13 Products under Development by Companies, H1 2014 14 Products under Investigation by Universities/Institutes, H1 2014 15 Mitochondrial Diseases - Pipeline by NeuroVive Pharmaceutical AB, H1 2014 16 Mitochondrial Diseases - Pipeline by Edison Pharmaceuticals, Inc., H1 2014 17 Mitochondrial Diseases - Pipeline by ElexoPharm GmbH, H1 2014 18 Assessment by Monotherapy Products, H1 2014 19 Number of Products by Stage and Target, H1 2014 21 Number of Products by Stage and Mechanism of Action, H1 2014 23 Number of Products by Stage and Route of Administration, H1 2014 25 Number of Products by Stage and Molecule Type, H1 2014 27 Mitochondrial Diseases Therapeutics - Recent Pipeline Updates, H1 2014 39 Mitochondrial Diseases - Dormant Projects, H1 2014 46 Mitochondrial Diseases - Discontinued Products, H1 2014 47
List of Figures
Number of Products under Development for Mitochondrial Diseases, H1 2014 7 Number of Products under Development for Mitochondrial Diseases - Comparative Analysis, H1 2014 8 Number of Products under Development by Companies, H1 2014 9 Comparative Analysis by Clinical Stage Development, H1 2014 12 Comparative Analysis by Early Stage Products, H1 2014 13 Assessment by Monotherapy Products, H1 2014 19 Number of Products by Top 10 Target, H1 2014 20 Number of Products by Stage and Top 10 Target, H1 2014 21 Number of Products by Top 10 Mechanism of Action, H1 2014 22 Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 23 Number of Products by Top 10 Route of Administration, H1 2014 24 Number of Products by Stage and Top 10 Route of Administration, H1 2014 25 Number of Products by Top 10 Molecule Type, H1 2014 26 Number of Products by Stage and Top 10 Molecule Type, H1 2014 27